Amphastar P (AMPH) - Total Liabilities
Based on the latest financial reports, Amphastar P (AMPH) has total liabilities worth $975.61 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore AMPH long-term investments to assets to see how much of total assets are deployed in long-term investments.
Amphastar P - Total Liabilities Trend (2012–2025)
This chart illustrates how Amphastar P's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see AMPH total asset value.
Amphastar P Competitors by Total Liabilities
The table below lists competitors of Amphastar P ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ratos AB (publ)
ST:RATO-B
|
Sweden | Skr12.45 Billion |
|
Procter & Gamble Health Limited
NSE:PGHL
|
India | Rs2.75 Billion |
|
Pacira BioSciences, Inc.
NASDAQ:PCRX
|
USA | $572.01 Million |
|
Neo Performance Materials Inc
TO:NEO
|
Canada | CA$356.63 Million |
|
Amerant Bancorp Inc.
NYSE:AMTB
|
USA | $8.84 Billion |
|
Jiangxi Hungpai New Material Co Ltd
SHG:605366
|
China | CN¥1.28 Billion |
|
Hwaxin Environmental Co. Ltd. A
SHE:301265
|
China | CN¥632.55 Million |
|
Plymouth Industrial REIT Inc
NYSE:PLYM
|
USA | $1.02 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Amphastar P's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See AMPH equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.40 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.27 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.56 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Amphastar P's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Amphastar P (2012–2025)
The table below shows the annual total liabilities of Amphastar P from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $840.49 Million | -0.55% |
| 2024-12-31 | $845.17 Million | -3.24% |
| 2023-12-31 | $873.49 Million | +309.46% |
| 2022-12-31 | $213.33 Million | -5.61% |
| 2021-12-31 | $226.01 Million | +23.83% |
| 2020-12-31 | $182.51 Million | +14.47% |
| 2019-12-31 | $159.44 Million | +6.86% |
| 2018-12-31 | $149.20 Million | +27.16% |
| 2017-12-31 | $117.34 Million | +19.14% |
| 2016-12-31 | $98.48 Million | +4.08% |
| 2015-12-31 | $94.63 Million | -11.98% |
| 2014-12-31 | $107.51 Million | +23.29% |
| 2013-12-31 | $87.20 Million | +3.77% |
| 2012-12-31 | $84.04 Million | -- |
About Amphastar P
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mi… Read more